Abstract Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Tebotelimab, a bispecific PD-1× LAG-3 DART molecule that blocks both PD-1 and LAG-3,
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

To prevent the destruction of tissues owing to excessive and/or inappropriate immune
responses, immune cells are under strict check by various regulatory mechanisms at …

Tumor development and metastasis are facilitated by the complex interactions between
cancer cells and their microenvironment, which comprises stromal cells and extracellular …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Summary Lymphocyte activation gene-3 (LAG-3) is a potent inhibitory co-receptor; yet, its
functional ligand remains elusive, with distinct potential ligands identified. Here, we …

LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin
superfamily, is confirmed to be expressed on activated immune cells, mainly including …

The T‐cell response is central in the adaptive immune‐mediated elimination of pathogen‐
infected and/or cancer cells. This activated T‐cell response can inflict an overwhelming …